Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706795 · ClinicalTrials.gov registry record · Phase 2
Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia
A Phase 2 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02706795 is a Phase 2 study that has completed, run by Revance Therapeutics. The registered enrollment target is 37 participants.
The verdict
NCT02706795, a Phase 2 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is an open-label, dose-escalation study to assess the safety and preliminary efficacy of daxibotulinumtoxinA in subjects with isolated cervical dystonia (CD).
Interventions
- BIOLOGICAL DaxibotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-07-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02706795
The ClinicalTrials.gov registry entry for NCT02706795 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DaxibotulinumtoxinA is the first listed.
NCT02706795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02706795 about?
NCT02706795 is a clinical study titled "Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia". This is an open-label, dose-escalation study to assess the safety and preliminary efficacy of daxibotulinumtoxinA in subjects with isolated cervical dystonia (CD).
What is the current status of trial NCT02706795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2015-09. Estimated completion is 2017-07-17.
What interventions are being tested in trial NCT02706795?
The interventions under investigation include: DaxibotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT02706795?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.